Clinical trials · Ohio
Chronic Lymphocytic Leukemia clinical trials in Ohio
We’re tracking 47 recruiting chronic lymphocytic leukemia studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT07218341RecruitingPhase 4
Continuing pirtobrutinib for CLL or SLL patients
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Cincinnati, OhioAges 18 years+ - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Cincinnati, OhioAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Cincinnati, OhioAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Cleveland, OhioAges 18 years+ - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Dayton, OhioAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Columbus, OhioAges 13–90 - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Beavercreek, OhioAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
Columbus, OhioAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Akron, OhioAges 40–75 - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Athens, OhioAges 65 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Cincinnati, OhioAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Canton, OhioAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Columbus, OhioAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Cincinnati, OhioAges 13 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Cincinnati, OhioAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
Columbus, OhioAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Cincinnati, OhioAges 18 years+ - NCT05336812RecruitingPhase 2
Acalabrutinib with venetoclax or obinutuzumab for untreated CLL
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
Columbus, OhioAges 18 years+ - NCT05417165RecruitingPhase 2
Pneumococcal vaccine plan for CLL or SLL patients
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
Columbus, OhioAges 18 years+ - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Maumee, OhioAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Cincinnati, OhioAges birth–38 years - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Cleveland, OhioAges 18 years+ - NCT06466122RecruitingPhase 2
Pirtobrutinib plus Venetoclax for resistant CLL or SLL
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Columbus, OhioAges 18 years+
Chronic Lymphocytic Leukemia trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting chronic lymphocytic leukemia studies listed above.
- The Ohio State University Wexner Medical Center · 15 studies
- Cleveland Clinic · 4 studies
- Oncology Hematology Care · 4 studies
- Columbus Oncology and Hematology Associates Inc · 3 studies
- Doctors Hospital · 3 studies
- Dublin Methodist Hospital · 3 studies
- Grady Memorial Hospital · 3 studies
- Grant Medical Center · 3 studies
What taking part in a chronic lymphocytic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Chronic Lymphocytic Leukemia trials in other states
Common questions
- Are there chronic lymphocytic leukemia clinical trials in Ohio?
- Yes. We're currently tracking 47 recruiting chronic lymphocytic leukemia studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic lymphocytic leukemia study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic lymphocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic lymphocytic leukemia studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.